LRRK2 levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodies-Reference-Cited by-同舟云学术

LRRK2 levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodies

Published:2016-12-02 Issue:3 Volume:32 Page:423-432
ISSN:0885-3185
Container-title:Movement Disorders
language:en
Short-container-title:Mov Disord.

Author:

Dzamko Nicolas¹²,Gysbers Amanda M.²,Bandopadhyay Rina³,Bolliger Marc F.⁴,Uchino Akiko⁵,Zhao Ye¹,Takao Masaki⁵⁶,Wauters Sandrine³,Berg Wilma D. J.⁷,Takahashi‐Fujigasaki Junko⁵,Nichols R. Jeremy⁴,Holton Janice L.³,Murayama Shigeo⁵,Halliday Glenda M.¹²^ORCID

Affiliation:

1. School of Medical SciencesUniversity of New South WalesKensington Australia

2. Neuroscience Research AustraliaRandwick Australia

3. Queen Square Brain Bank, UCL Institute of NeurologyUniversity College LondonLondon UK

4. Parkinson's Institute and Clinical CenterSunnyvale California USA

5. Department of Neuropathology, Brain Bank for Aging ResearchTokyo Metropolitan Geriatric Hospital and Institute of GerontologyTokyo Japan

6. Department of NeurologySaitama Medical University, International Medical CentreSaitama Japan

7. Department of Anatomy and Neurosciences, Neuroscience Campus AmsterdamVU University Medical CentreAmsterdam The Netherlands

Funder

Michael J. Fox Foundation for Parkinson's Disease Research

Australia Foundation

National Health and Medical Research Council of Australia

Reta Lila Weston Trust

Multiple System Atrophy Trust

Alzheimer's Research UK

CBD Solutions

Stichting Parkinson Fonds, Internationale Stichting Alzheimer onderzoek

ZonMW Memorabel Deltaplan Dementia

Queen Square Brain Bank

Reta Lila Weston Institute for Neurological Studies and the Medical Research Council UK

National Institute for Health Research University College London Hospitals Biomedical Research Centre

Publisher

Wiley

Subject

Clinical Neurology,Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/mds.26892

Reference31 articles.

1. Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology

2. Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease

3. From The Cover: Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity

4. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity

5. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. LRRK2 in Parkinson's disease: upstream regulation and therapeutic targeting;Trends in Molecular Medicine;2024-08

2. Leucine-rich repeat kinase 2 (LRRK2) inhibitors for Parkinson’s disease: a patent review of the literature to date;Expert Opinion on Therapeutic Patents;2024-07-19

3. Low-dose radiation decreases Lrrk2 levels in the striatum of large mammalian brains: New venues to treat Parkinson's disease?;Parkinsonism & Related Disorders;2024-07

4. Experimental Animal Models of Prodromal Parkinson’s Disease;Journal of Parkinson's Disease;2024-02-24

5. Targeting LRRK2 mRNA stability in Parkinson’s disease;Trends in Neurosciences;2024-01